跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SANDOZ MOMETASONE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SANDOZ MOMETASONE
Authorized
STANDARD
SANDOZ MOMETASONE
Sandoz Canada, Inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
49a703cd6315c3ca
Company
Sandoz Canada, Inc.
Type
Standard
Approval Details
Approval Id
49a703cd6315c3ca
Drug Approval Canada Name
SANDOZ MOMETASONE
Product Name
SANDOZ MOMETASONE
Status
Marketed
Status Date
2016-07-27
Original Market Date
2016-07-27
Din
02449811
Drug Class
Human
Dosage Form
Spray, Metered Dose
Route Of Administration
Nasal
Schedule
Prescription
Ahfs
52:08.08
Atc Original
R01AD09 MOMETASONE
Atc Name
r 01 ad 09
Aig Number
0121732002
Company Name
Sandoz Canada, Inc.
Company Address
4600 Rue Armand-Frappier, Saint-Hubert, Quebec, Canada, J3Z 1G5
Company Detail Path
/organization/sandoz-canada-inc
Company Information
Pharmaceutical Company Name
Sandoz Canada, Inc.
Country Name
Canada
Website
http://www.sandoz.ca
Active Ingredients
MOMETASONE FUROATE (MOMETASONE FUROATE MONOHYDRATE)
50 MCG / ACT
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
49a703cd6315c3ca
Type
Standard
Back to Health Canada Approvals